Risk of neutropenia-related hospitalisation among clozapine initiators
Despite removal of the REMS programme, it is important for prescribers to monitor patients for neutropenia after initiating clozapine.
Authors
- Lauren V. Moran (ORCID: https://orcid.org/0000-0002-5185-1767)
- Ameet Sarpatwari (ORCID: https://orcid.org/0000-0001-5043-6206)
- Gita A. Toyserkani (ORCID: https://orcid.org/0000-0002-6946-6138)
- Heidi Zakoul (ORCID: https://orcid.org/0009-0008-3022-9013)
- Esther H. Zhou (ORCID: https://orcid.org/0000-0003-4608-6850)
- Cynthia LaCivita (ORCID: https://orcid.org/0009-0001-8680-9008)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Gerald J. Dal Pan (ORCID: https://orcid.org/0000-0003-4874-5864)
- Mufaddal Mahesri (ORCID: https://orcid.org/0000-0002-6684-2337)
- Jerry Avorn
- Joyce Lii
- Krista F Huybrechts
- Katsiaryna Bykov
- Su Been Lee
Institutions
- Brigham and Women's Hospital (US)
- United States Food and Drug Administration (US)
- Center for Drug Evaluation and Research (US)
- Harvard University (US)
Publication Details
- Journal
- BMJ Mental Health
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/bmjment-2025-302122
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Food and Drug Administration